Funding Opportunity
The London-based venture capital investor Abingworth, closed a GBP 84 million expansion of Abingworth Bioventures V LP, bringing the total funds for investment to GBP 392 million.
The new money was raised in an affiliated fund, Abingworth Bioventures V Co-Invest Growth Equity Fund LP, which will co-invest with Abingworth Bioventures V in growth equity companies.
The fund will allow Abingworth to participate more actively in growth equity investments in companies at the later stage of development with significantly larger capital requirements than venture capital start-ups. Abingworth says it will consider investments of up to GBP40 million in a single company.
“We are delighted to have raised additional finance under the current market conditions,” said Stephen Bunting, Managing Partner. “Abingworth now has a £392 million fund, allowing us to extend our role to a broader range of new investment opportunities in the life sciences and healthcare sector.”
Abingworth specialises in the life sciences and healthcare sector. The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
